SERB obtains US rights to SFJ’s ticagrelor reversal agent bentracimab
Bentracimab is a novel, monoclonal antibody fragment that reverses the antiplatelet activity of ticagrelor, an antiplatelet medicine marketed…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 May 23
Bentracimab is a novel, monoclonal antibody fragment that reverses the antiplatelet activity of ticagrelor, an antiplatelet medicine marketed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 May 23
The biotechnology company has entered negotiations with a major global pharmaceutical company, for the development and commercialisation of…
05 May 23
Under the terms of the agreement, Novocol Pharma will provide fill-finish and packaging for vaccines manufactured at Moderna’s…
08 Mar 23
The financing, led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly, will support Volastra’s portfolio…
28 Oct 22
Under the agreement, FDB will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød,…
09 Sep 22
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…
01 Aug 22
Under the new agreement with the US government, the biotechnology company will receive up to $1.74bn for 66…
13 Jul 22
GenScript ProBio will support ACT therapeutics’ CAR-T Platform (ACT platform), an immune cell-based cell and gene therapy technology…
12 Jul 22
Ionis will receive $55m from Roche, in exchange for licensing IONIS-FB-LRx and achieving a development milestone in the…
04 Jul 22
The company is entitled to receive a settlement fee of $55m and will assume responsibility for the marketing…